Drugs / LiveSpo Navax
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06148194 | Jan → May 2024 | respiratory tract infectious disorder | Anabio R&D | Completed | No outcome recorded |
| — | NCT05929599 | Jul 2023 → Jul 2024 overdue | pneumonia, respiratory syncytial virus infectious disease | National Children's Hospital, Vietnam | Active not recruiting | No outcome recorded |
| — | NCT05804123 | Oct 2021 → Apr 2024 | respiratory tract infectious disorder | Anabio R&D | Completed | No outcome recorded |
| — | NCT05378022 | Dec 2020 → Mar 2022 | viral respiratory tract infection | National Children's Hospital, Vietnam | Completed | No outcome recorded |
| — | NCT05164692 | Aug 2020 → Jun 2021 | respiratory tract infectious disorder | National Children's Hospital, Vietnam | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LiveSpo Navax | “LiveSpo Navax product is prepared in the form of NaCl 0.9% plus B. subtilis and B. clausii at 1 billion CFU/mL x 30 mL.” NCT06148194 ↗ |
| Modality | Other / unclassified | “liquid-suspension form containing Bacillus spores of safe B. subtilis ANA4 and B. clausii ANA39 strains” NCT05164692 ↗ |
| Route | Intranasal | “direct spraying of probiotics into the nose can be a fast and effective symptomatic treatment for ARTIs” NCT05164692 ↗ |